These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12678836)

  • 61. Peptidergic control of food intake in food-producing animals.
    Baile CA; Della-Fera MA
    Fed Proc; 1984 Nov; 43(14):2898-902. PubMed ID: 6092147
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.
    Fourmy D; Escrieut C; Archer E; Galès C; Gigoux V; Maigret B; Moroder L; Silvente-Poirot S; Martinez J; Fehrentz JA; Pradayrol L
    Pharmacol Toxicol; 2002 Dec; 91(6):313-20. PubMed ID: 12688374
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Involvement of endogenous CCK and CCK1 receptors in colonic motor function.
    Varga G; Bálint A; Burghardt B; D'Amato M
    Br J Pharmacol; 2004 Apr; 141(8):1275-84. PubMed ID: 15100163
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats.
    Wen D; Sun D; Zang G; Hao L; Liu X; Yu F; Ma C; Cong B
    Neuroscience; 2014 Sep; 277():14-25. PubMed ID: 24993476
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.
    Desai AJ; Dong M; Harikumar KG; Miller LJ
    Int J Obes Suppl; 2016 Dec; 6(Suppl 1):S22-S27. PubMed ID: 28685026
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Calcium and Neural Stem Cell Proliferation.
    Díaz-Piña DA; Rivera-Ramírez N; García-López G; Díaz NF; Molina-Hernández A
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612887
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intestinal Enteroendocrine Cells: Present and Future Druggable Targets.
    Atanga R; Singh V; In JG
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240181
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Marine Peptides: Bioactivities and Applications.
    Cheung RC; Ng TB; Wong JH
    Mar Drugs; 2015 Jun; 13(7):4006-43. PubMed ID: 26132844
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Appetite regulation and weight control: the role of gut hormones.
    Perry B; Wang Y
    Nutr Diabetes; 2012 Jan; 2(1):e26. PubMed ID: 23154682
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Obesity pharmacotherapy: current perspectives and future directions.
    Misra M
    Curr Cardiol Rev; 2013 Feb; 9(1):33-54. PubMed ID: 23092275
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.
    Cawston EE; Miller LJ
    Br J Pharmacol; 2010 Mar; 159(5):1009-21. PubMed ID: 19922535
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.
    Berna MJ; Tapia JA; Sancho V; Jensen RT
    Curr Opin Pharmacol; 2007 Dec; 7(6):583-92. PubMed ID: 17997137
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.
    Berna MJ; Jensen RT
    Curr Top Med Chem; 2007; 7(12):1211-31. PubMed ID: 17584143
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Current and novel approaches to the drug therapy of obesity.
    Chaput JP; Tremblay A
    Eur J Clin Pharmacol; 2006 Oct; 62(10):793-803. PubMed ID: 16937118
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CCK1R agonists: a promising target for the pharmacological treatment of obesity.
    Szewczyk JR; Laudeman C
    Curr Top Med Chem; 2003; 3(8):837-54. PubMed ID: 12678836
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
    Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
    Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.
    Harikumar KG; Coudrat T; Desai AJ; Dong M; Dengler DG; Furness SGB; Christopoulos A; Wootten D; Sergienko EA; Sexton PM; Miller LJ
    Front Endocrinol (Lausanne); 2021; 12():789957. PubMed ID: 34950108
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evidence for a functional role of cholecystokinin receptors in the rat thyroid gland.
    Ginda WJ
    Folia Histochem Cytobiol; 2001; 39(4):331-4. PubMed ID: 11766768
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.